DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
QDEL logo

QuidelOrtho Corporation Stock Price

NasdaqGS:QDEL Community·US$833.2m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

QDEL Share Price Performance

US$11.78
-16.79 (-58.77%)
​
US$14.67
Fair Value
US$11.78
-16.79 (-58.77%)
19.7% undervalued intrinsic discount
US$14.67
Fair Value
Price US$11.78
AnalystConsensusTarget US$14.67
AnalystHighTarget US$20.00
AnalystLowTarget US$12.00
Wed, 26 Aug 26
Fair ValueUS$14.67
Share Pricen/a

QDEL Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$14.67 19.7% undervalued intrinsic discount

Global Expansion And Decentralized Testing Will Unlock Future Potential

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$20 41.1% undervalued intrinsic discount

Expanding Access And Aging Demographics Will Redefine Diagnostics

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$12 1.8% undervalued intrinsic discount

Debt And Costs Will Squeeze Margins As Markets Rebound

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
QDEL logo
QuidelOrtho
19.7% undervalued intrinsic discount

Global Expansion And Decentralized Testing Will Unlock Future Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Aug
Read Narrative
QDEL logo
QuidelOrtho
41.1% undervalued intrinsic discount
Updated

Expanding Access And Aging Demographics Will Redefine Diagnostics

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 9 Sep
Read Narrative
QDEL logo
QuidelOrtho
1.8% undervalued intrinsic discount

Debt And Costs Will Squeeze Margins As Markets Rebound

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 28 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
QDEL logo

QDEL: Point Of Care Sale And Reset Expectations Will Support Future Earnings

Fair Value: US$20 41.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
QDEL logo

QDEL: Planned Unit Sale And Debt Refinancing Will Shape Future Returns

Fair Value: US$14.67 19.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
QDEL logo

QDEL: Debt Reduction Plans And Asset Sale Will Likely Limit Share Upside

Fair Value: US$12 1.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with low risk.

3 Risks
2 Rewards
View Full Analysis

QuidelOrtho Corporation Key Details

US$2.7b

Revenue

US$1.5b

Cost of Revenue

US$1.2b

Gross Profit

US$2.2b

Other Expenses

-US$1.0b

Earnings

Last Reported Earnings
Jun 28, 2026
Next Reporting Earnings
n/a
-15.29
44.86%
-39.20%
162.9%
View Full Analysis

About QDEL

Founded
1979
Employees
6500
CEO
Brian Blaser
WebsiteView website
www.quidelortho.com

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Recent QDEL News & Updates

User avatar
Narrative Update • Sep 09

QDEL: Point Of Care Sale And Reset Expectations Will Support Future Earnings

QuidelOrtho's updated analyst price target of $20, revised from $38, reflects analysts' refreshed models that incorporate more muted revenue growth assumptions, a slightly higher discount rate, modestly lower profit margin expectations, and a reduced future P/E multiple, in line with recent price target moves from $11 to $12 and from $13 to $18 across the Street. Analyst Commentary Recent research updates on QuidelOrtho show a mix of caution and optimism, with some bullish analysts highlighting potential upside in the stock.
User avatar
Narrative Update • Aug 26

QDEL: Planned Unit Sale And Debt Refinancing Will Shape Future Returns

QuidelOrtho's analyst price target has shifted from $12 to about $14.67, as analysts point to refreshed models and updated assumptions following recent target changes from $11 to $12 and from $13 to $18 at major firms. Analyst Commentary Recent research updates on QuidelOrtho give you a mixed but clearer picture of how the stock is being framed on Wall Street.
User avatar
Narrative Update • Aug 12

QDEL: Planned Unit Sale And Heavier Debt Load Will Pressure Returns

Analysts have trimmed their fair value estimate for QuidelOrtho from $20.50 to $12.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E multiples, alongside recent price target adjustments to $18 and $12 from different research firms. Analyst Commentary Recent research updates on QuidelOrtho show a mix of cautious and more constructive views on the stock, with modest price target adjustments and differing opinions on risk and execution.

Recent updates

No updates

QuidelOrtho Corporation Competitors

AVAH logo

Aveanna Healthcare Holdings

Symbol: NasdaqGS:AVAH
Market cap: US$3.0b
BKD logo

Brookdale Senior Living

Symbol: NYSE:BKD
Market cap: US$2.9b
TMDX logo

TransMedics Group

Symbol: NasdaqGM:TMDX
Market cap: US$2.8b
GRDN logo

Guardian Pharmacy Services

Symbol: NYSE:GRDN
Market cap: US$2.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide